XML 58 R5.htm IDEA: XBRL DOCUMENT v2.4.1.9
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
3 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Cash flows from operating activities:    
Net income $ 76,021us-gaap_NetIncomeLoss $ 68,305us-gaap_NetIncomeLoss
Adjustments to reconcile net income to net cash (used in) provided by operating activities:    
Depreciation and amortization 16,027us-gaap_DepreciationDepletionAndAmortization 11,530us-gaap_DepreciationDepletionAndAmortization
Non-cash compensation expense 103,759us-gaap_ShareBasedCompensation 75,785us-gaap_ShareBasedCompensation
Non-cash interest expense 2,358us-gaap_OtherNoncashExpense 5,916us-gaap_OtherNoncashExpense
Losses on Extinguishment of Debt 942us-gaap_GainsLossesOnExtinguishmentOfDebt 0us-gaap_GainsLossesOnExtinguishmentOfDebt
Other non-cash charges and expenses, net 6,006us-gaap_OtherNoncashIncomeExpense 3,761us-gaap_OtherNoncashIncomeExpense
Deferred Taxes (10,888)us-gaap_IncreaseDecreaseInDeferredIncomeTaxes (5,761)us-gaap_IncreaseDecreaseInDeferredIncomeTaxes
Changes in assets and liabilites    
Increase in Sanofi, Bayer HealthCare, and trade accounts receivable (321,063)us-gaap_IncreaseDecreaseInAccountsReceivable (92,529)us-gaap_IncreaseDecreaseInAccountsReceivable
Increase in Inventories (5,932)us-gaap_IncreaseDecreaseInInventories (15,550)us-gaap_IncreaseDecreaseInInventories
Decrease (increase) in prepaid expenses and other assets 35,874us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets (20,898)us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
(Decrease) increase in deferred revenue (16,140)us-gaap_IncreaseDecreaseInDeferredRevenue 37,107us-gaap_IncreaseDecreaseInDeferredRevenue
Increase (decrease) in accounts payable, accrued expenses and other liabilities 25,534us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities (14,139)us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
Total adjustments (163,523)us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities (14,778)us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
Net cash (used in) provided by operating activities (87,502)us-gaap_NetCashProvidedByUsedInOperatingActivities 53,527us-gaap_NetCashProvidedByUsedInOperatingActivities
Cash flows from investing activities:    
Purchases of marketable securities (95,775)us-gaap_PaymentsToAcquireMarketableSecurities (253,878)us-gaap_PaymentsToAcquireMarketableSecurities
Sales or maturities of marketable securities 80,456us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities 82,469us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities
Capital expenditures (114,162)us-gaap_PaymentsToAcquireProductiveAssets (64,822)us-gaap_PaymentsToAcquireProductiveAssets
Net cash used in investing activities (129,481)us-gaap_NetCashProvidedByUsedInInvestingActivities (236,231)us-gaap_NetCashProvidedByUsedInInvestingActivities
Cash flows from financing activities:    
Proceeds (payments) in connection with facility and capital lease obligations 6,738us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities (262)us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities
Repayments of convertible senior notes (16,686)us-gaap_RepaymentsOfConvertibleDebt 0us-gaap_RepaymentsOfConvertibleDebt
Payments in connection with deduction of outstanding warrants (124,531)us-gaap_PaymentsForRepurchaseOfWarrants 0us-gaap_PaymentsForRepurchaseOfWarrants
Proceeds from issuance of Common Stock 76,273us-gaap_ProceedsFromIssuanceOfCommonStock 55,042us-gaap_ProceedsFromIssuanceOfCommonStock
Payments in connection with Common Stock tendered for employee tax obligations (21,192)us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation (63,086)us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation
Excess tax benefit from stock-based compensation 155,569us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities 117,260us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
Net cash provided by financing activities 76,171us-gaap_NetCashProvidedByUsedInFinancingActivities 108,954us-gaap_NetCashProvidedByUsedInFinancingActivities
Net decrease in cash and cash equivalents (140,812)us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease (73,750)us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease
Cash and cash equivalents at beginning of period 648,719us-gaap_CashAndCashEquivalentsAtCarryingValue 535,608us-gaap_CashAndCashEquivalentsAtCarryingValue
Cash and cash equivalents at end of period $ 507,907us-gaap_CashAndCashEquivalentsAtCarryingValue $ 461,858us-gaap_CashAndCashEquivalentsAtCarryingValue